Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call May 7, 2026 8:30 AM EDT
Company Participants
Brennan Doyle - VP & Head of Investor Relations
Jeffrey Dayno - President, CEO & Director
Adam Zaeske - Executive VP & Chief Commercial Officer
Kumar Budur - Executive VP and Chief Medical & Scientific Officer
Glenn Reicin - Chief Financial Officer
Peter Anastasiou - Chief Operating Officer
Conference Call Participants
David Amsellem - Piper Sandler & Co., Research Division
Ami Fadia - Needham & Company, LLC, Research Division
Graig Suvannavejh - Mizuho Securities USA LLC, Research Division
Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division
Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division
So Youn Shim - UBS Investment Bank, Research Division
Jason Gerberry - BofA Securities, Research Division
Presentation
Operator
Hello, and thank you for standing by. My name is Mel and I will be your conference operator for today. At this time, I would like to welcome everyone to the Harmony Biosciences First Quarter 2026 Financial Results. [Operator Instructions] Thank you.
I would now like to turn the call over to Brennan Doyle, Head of Investor Relations. Sir, please go ahead.
Brennan Doyle
VP & Head of Investor Relations
Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences first quarter 2026 financial result and provide a business update. Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP financial measures.
Our speakers on today's call are Dr. Jeffrey Duyno, President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Badur, Chief Medical and Scientific Officer; Glenn Reicin, Chief Financial Officer; and Peter Anastasiou, Chief Operating Officer.
As a reminder, we
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。